News Release

Antibody response of 3-dose COVID-19 vaccination schedule in immunocompromised patients with hematologic cancers

JAMA Oncology

Peer-Reviewed Publication

JAMA Network

About The Study: In this study that included 584 immunocompromised patients with hematologic cancers, a third Moderna COVID-19 vaccination was associated with significantly improved SARS-CoV-2 antibody concentrations comparable to those obtained by healthy individuals after the standard two-dose Moderna vaccination schedule.

Authors: Mette D. Hazenberg, M.D., Ph.D., of the University of Amsterdam, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ 

(doi:10.1001/jamaoncol.2022.3227)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2022.3227?guestAccessKey=0b9a95d7-73d1-49c0-a5a8-c690dae47ecc&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=081122


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.